BriaCell Therapeutics Shares Are Trading Higher After the Company Announced It Dosed the First Patient in Its Phase 1/2 Study of Bria-OTS.

Benzinga00:47

Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy

BenzingaNov 21 20:51

BriaCell Announces First Patient Dosed With Bria-OTS in Metastatic Breast Cancer Study

GlobeNewswireNov 21 20:50

Express News | Briacell Announces First Patient Dosed With Bria-Ots™ in Metastatic Breast Cancer Study

BreakingsNov 21 20:50

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

GlobeNewswireNov 8 20:50

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium, December 10 – 13

GlobeNewswireNov 4 20:50